Clinical characteristics of patients who preferred migraine prevention treatment with CGRP monoclonal antibodies

被引：0
|
作者：
Vashchenko, N. [1 ,2 ]
Skorobogatykh, K. [2 ]
Azimova, J. [2 ]
Korobkova, D. [2 ]
机构：
[1] Sechenov Univ, Dept Neurol, Moscow, Russia
[2] Univ Headache Clin, Moscow, Russia
来源：
JOURNAL OF HEADACHE AND PAIN | 2021年 / 22卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P0341
引用
收藏
页码：122 / 122
页数：1
相关论文
共 50 条
  • [1] Clinical characteristics of patients who preferred migraine prevention treatment with CGRP monoclonal antibodies
    Vashchenko, N.
    Skorobogatykh, K.
    Azimova, J.
    Korobkova, D.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 182 - 182
  • [2] Monoclonal Antibodies to CGRP or Its Receptor for Migraine Prevention
    Moriarty, Maureen
    Mallick-Searle, Theresa
    Barch, Carol A.
    Oas, Kim
    JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2019, 15 (10): : 717 - +
  • [3] CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine
    Israel, Heike
    Neeb, Lars
    Reuter, Uwe
    CURRENT PAIN AND HEADACHE REPORTS, 2018, 22 (05)
  • [4] Monoclonal antibodies against CGRP for the treatment of migraine
    Alberto Choreno-Parra, Jose
    Carnalla-Cortes, Martha
    Martinez-Zuniga, Nayeli
    Guadarrama-Ortiz, Parmenides
    REVISTA MEXICANA DE NEUROCIENCIA, 2018, 19 (04): : 45 - 61
  • [5] CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine
    Heike Israel
    Lars Neeb
    Uwe Reuter
    Current Pain and Headache Reports, 2018, 22
  • [6] Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
    de Meira Grava Simioni, Caio Vinicius
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2022, 80 (05) : 214 - 217
  • [7] Anti-CGRP monoclonal antibodies: migraine prevention in patients with psychiatric comorbidities
    di Cola, Francesca Schiano
    Ceccardi, Giulia
    Caratozzolo, Salvatore
    Bolchini, Marco
    Di Pasquale, Michele
    Rao, Renata
    Padovani, Alessandro
    CEPHALALGIA, 2023, 43 (1supp) : 252 - 253
  • [8] CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications
    Dodick, David W.
    CEPHALALGIA, 2019, 39 (03) : 445 - 458
  • [9] Placebo effects in clinical trials of anti-CGRP monoclonal antibodies for migraine prevention
    Regnier, S.
    Lee, X. Ying
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [10] CGRP Monoclonal Antibodies in the Treatment of Migraine in Elderly Patients: A Single Center Experience
    Patel, P.
    Lee, M.
    Shadbehr, N.
    Kriegler, J. S.
    Mays, M.
    Burstein, T.
    Ahmed, Z.
    HEADACHE, 2020, 60 : 8 - 8
12345